LORLADX Lorlatinib
Lorlatinib is a third-generation drug for the treatment of non-small cell lung cancer (NSCLC). It has strong inhibitory effects on dual receptor tyrosine kinase (RTK) of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1). It is used to treat patients who have previously received at least one ALK inhibitor, such as the first-generation ALK inhibitor crizotinib.
View Product